Peter Ellinghaus1, Elisabeth Perzborn2, Peter Hauenschild3, Christoph Gerdes4, Stefan Heitmeier5, Mayken Visser6, Holger Summer7, Volker Laux8. 1. Global Biomarkers Research, Bayer Pharma AG, Wuppertal, Germany. Electronic address: peter.ellinghaus@bayer.com. 2. Formerly Acute Care Diseases Research, Bayer Pharma AG, Wuppertal, Germany. Electronic address: elisabeth.perzborn@bayer.com. 3. Global Biomarkers Research, Bayer Pharma AG, Wuppertal, Germany. Electronic address: peter.hauenschild@bayer.com. 4. Acute Care Diseases Research, Bayer Pharma AG, Wuppertal, Germany. Electronic address: christoph.gerdes@bayer.com. 5. Acute Care Diseases Research, Bayer Pharma AG, Wuppertal, Germany. Electronic address: stefan.heitmeier@bayer.com. 6. Acute Care Diseases Research, Bayer Pharma AG, Wuppertal, Germany. Electronic address: mayken.visser@bayer.com. 7. Lead Generation & Optimization, Bayer Pharma AG, Wuppertal, Germany. Electronic address: holger.summer@bayer.com. 8. Acute Care Diseases Research, Bayer Pharma AG, Wuppertal, Germany. Electronic address: volker.laux@bayer.com.
Abstract
INTRODUCTION: In addition to its central role in coagulation, thrombin is involved in non-hemostatic activities such as inflammation. Direct inhibition of thrombin activity (e.g. with dabigatran) or reducing its generation by inhibition of Factor Xa (e.g. with rivaroxaban) may therefore have anti-inflammatory effects. MATERIALS AND METHODS: Microarray experiments were performed to identify transcriptome-wide changes in mRNA expression levels induced by thrombin in the presence and absence of the PAR-1 antagonist vorapaxar in primary human umbilical vein endothelial cells (HUVECs). On this basis, HUVECs were incubated with recalcified plasma, with or without rivaroxaban (0.3-3000nM), dabigatran (0.3-10,000nM), or vorapaxar (0.3-10nM). Expression levels of preselected pro-inflammatory genes were quantified by real-time PCR. RESULTS: Vorapaxar abolished 67 of the 69 transcripts altered by more than twofold on addition of thrombin to HUVECs. ELAM-1, VCAM-1, ICAM-1, MCP-1, IL-8, CXCL1, and CXCL2 were among the genes most strongly induced by thrombin. Inflammatory gene expression after stimulation of thrombin generation was concentration-dependently suppressed by vorapaxar, dabigatran, and rivaroxaban. However, dabigatran at low concentrations (3-300nM) increased significantly the expression levels of CXCL1, CXCL2, IL-8, ELAM-1, MCP-1, and tissue factor. CONCLUSION: In HUVECs, plasma-induced transcriptional changes are mediated by thrombin-induced PAR-1 activation. Rivaroxaban downregulated the expression of pro-inflammatory markers and tissue factor to a similar extent to dabigatran.
INTRODUCTION: In addition to its central role in coagulation, thrombin is involved in non-hemostatic activities such as inflammation. Direct inhibition of thrombin activity (e.g. with dabigatran) or reducing its generation by inhibition of Factor Xa (e.g. with rivaroxaban) may therefore have anti-inflammatory effects. MATERIALS AND METHODS: Microarray experiments were performed to identify transcriptome-wide changes in mRNA expression levels induced by thrombin in the presence and absence of the PAR-1 antagonist vorapaxar in primary human umbilical vein endothelial cells (HUVECs). On this basis, HUVECs were incubated with recalcified plasma, with or without rivaroxaban (0.3-3000nM), dabigatran (0.3-10,000nM), or vorapaxar (0.3-10nM). Expression levels of preselected pro-inflammatory genes were quantified by real-time PCR. RESULTS:Vorapaxar abolished 67 of the 69 transcripts altered by more than twofold on addition of thrombin to HUVECs. ELAM-1, VCAM-1, ICAM-1, MCP-1, IL-8, CXCL1, and CXCL2 were among the genes most strongly induced by thrombin. Inflammatory gene expression after stimulation of thrombin generation was concentration-dependently suppressed by vorapaxar, dabigatran, and rivaroxaban. However, dabigatran at low concentrations (3-300nM) increased significantly the expression levels of CXCL1, CXCL2, IL-8, ELAM-1, MCP-1, and tissue factor. CONCLUSION: In HUVECs, plasma-induced transcriptional changes are mediated by thrombin-induced PAR-1 activation. Rivaroxaban downregulated the expression of pro-inflammatory markers and tissue factor to a similar extent to dabigatran.
Authors: Jacob S Brenner; Kartik Bhamidipati; Patrick M Glassman; N Ramakrishnan; Depeng Jiang; Andrew J Paris; Jacob W Myerson; Daniel C Pan; Vladimir V Shuvaev; Carlos H Villa; Elizabeth D Hood; Raisa Kiseleva; Colin F Greineder; Ravi Radhakrishnan; Vladimir R Muzykantov Journal: Nanomedicine Date: 2017-01-05 Impact factor: 5.307
Authors: Ihsan Gadi; Sameen Fatima; Berend Isermann; Khurrum Shahzad; Ahmed Elwakiel; Sumra Nazir; Moh'd Mohanad Al-Dabet; Rajiv Rana; Fabian Bock; Jayakumar Manoharan; Dheerendra Gupta; Ronald Biemann; Bernhard Nieswandt; Ruediger Braun-Dullaeus; Christian Besler; Markus Scholz; Robert Geffers; John H Griffin; Charles T Esmon; Shrey Kohli Journal: Circ Res Date: 2020-12-23 Impact factor: 17.367
Authors: Chae Ho Lim; Qi Sun; Karan Ratti; Soung-Hoon Lee; Ying Zheng; Makoto Takeo; Wendy Lee; Piul Rabbani; Maksim V Plikus; Jason E Cain; David H Wang; D Neil Watkins; Sarah Millar; M Mark Taketo; Peggy Myung; George Cotsarelis; Mayumi Ito Journal: Nat Commun Date: 2018-11-21 Impact factor: 14.919